Healthcare
Vivos Therapeutics, Inc.(VVOS)
Live Price
Offline$0.50
-2.15% today
1Y Change
-80.54%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- โ
- Revenue Growth
- +16.0%
- EPS Growth
- +7.2%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Vivos Therapeutics, Inc. (VVOS) is a Healthcare stock with listed on NASDAQ. The stock last traded around $0.50 and down 80.5% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +16.0%, EPS growth of +7.2%, a dividend yield of 0.0%. What stands out right now is revenue +16.0%, EPS +7.2%, free cash flow -32.8% with operating margin -114.1% and ROIC -123.2%. Valuation is more restrained than many high-expectation growth names at price/sales 0.3. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines VVOS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+16.0% vs +7.6% peer median
Operating Margin
Below sector median
-114.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +16.0% and EPS at +7.2%, with operating margin around -114.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +8.5% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | +4.3% | +19.7% | โ |
2026 Mar 26, 2026 | +7.1% | -3.4% | +10.9% | -29.2% |
2025 Nov 19, 2025 | +7.5% | -10.2% | -5.1% | -16.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VVOS
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VVOS Max Drawdown
-91.77%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VVOS and SPY.
Company Overview
Vivos Therapeutics, Inc.
NASDAQ Capital Market
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. Vivos Therapeutics also offers VivoScore Program, a screening and home sleep test in adults and children. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
- Leadership
- R. Kirk Huntsman
- IPO Date
- Dec 11, 2020
- Employees
- 109
- Street Address
- 9137 Ridgeline Boulevard
- Mailing
- Highlands Ranch, CO, 80129
- Region
- Highlands Ranch, CO, US
- Reporting Currency
- USD
- Investor Line
- 866 908 4867
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.3
- Price/Book
- โ
Growth
- Revenue
- +16.0%
- EPS
- +7.2%
- Free Cash Flow
- -32.8%
Profitability
- Gross Margin
- 60.4%
- Operating Margin
- -114.1%
- Net Margin
- -121.7%
- ROE
- -846.5%
- ROIC
- -123.2%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.24
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.